$13.6 Billion Pours In! AI Drug Discovery Gallops Forward
Time：
2026-05-11 17:16
Author：
xieyijun
The Oligonucleotide Track: Mass-Producing the Next Generation of Blockbuster Drugs
Time：
2026-05-10 19:18
Author：
xieyijun
China’s Innovative Drug Mandate: Let MNCs Knock on the Door Initiative
Time：
2026-05-09 18:22
Author：
xieyijun
Unlock access to world-class global resource networking!
Time：
2026-05-09 09:29
Author：
xieyijun
One Platform, One Check, Two Paths for NewCo
Nine out of ten pipeline assets originate from China.
Time：
2026-05-09 08:14
Author：
xieyijun
CPIC 2026丨Roundtable: The Evolution and Ecosystem Restructuring of Global BD for Innovative Drugs
From "Borrowing a Boat" to "Building Our Own"
Time：
2026-05-08 16:20
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务